Wednesday, February 09, 2022 REC2 The REC2 (E2805) trial: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma has been permanently closed by the lead group. This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer. MYX1 The MYX1 trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies has been permanently closed. The MCRN-003/MYX1 clinical trial was conducted collaboratively between the Canadian Myeloma Research Group (previously known as the Myeloma Canada Research Network) and the Canadian Cancer Trials Group. The trial evaluated a once-weekly carfilzomib dosing regimen, more convenient for patients and more cost-effective for the health care system. The primary endpoint was met with overall response rate over 80%. Dr. Christopher Venner from the Cross Cancer Institute in Edmonton was the Study Chair.
